Nutriband receives FDA feedback on abuse deterrent fentanyl patch
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch
October 28, 2025 7:00 AM EDTNutriband met with US FDA to obtain feedback on the Chemistry, Manufacturing, and Controls plans for AVERSA FENTANYL (abuse deterrent transdermal system) through commercialization.
Nutriband received final meeting minutes from FDA and is incorporating the feedback into the development program as it moves forward to an IND filing in support of a Human Abuse Potential (HAP) clinical study for the product.
ORLANDO, Fla., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB)(NASDAQ: NTRBW), a company engaged in the development of prescription transdermal... More
